Epidemiology of Parkinson's disease. The Lancet, pp.525-535, 2006. ,
The Neuropathology Of Parkinson???S Disease, Journal of neuropathology and experimental neurology, vol.55, pp.259-272, 1996. ,
DOI : 10.1007/978-1-4613-0759-4_2
Parkinson's disease: clinical features and diagnosis, Journal of Neurology, Neurosurgery & Psychiatry, vol.79, issue.4, pp.368-376131045, 2007. ,
DOI : 10.1136/jnnp.2007.131045
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease, Journal of Cerebral Blood Flow & Metabolism, vol.44, issue.9, pp.1198-1212, 2006. ,
DOI : 10.1159/000054941
Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system, Parkinsonism & Related Disorders, vol.4, issue.2, pp.1236-1239, 1960. ,
DOI : 10.1016/S1353-8020(98)00012-1
Motor Score of the Unified Parkinson Disease Rating Scale as a Good Predictor of Lewy Body???Associated Neuronal Loss in the Substantia Nigra, Archives of Neurology, vol.63, issue.4, pp.584-588, 2006. ,
DOI : 10.1001/archneur.63.4.584
Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways, Neurology, vol.65, issue.11, pp.1716-1722, 2005. ,
DOI : 10.1212/01.wnl.0000191154.78131.f6
Oxidative stress in Parkinson's disease, Annals of Neurology, vol.83, issue.S3, pp.26-36, 2003. ,
DOI : 10.1042/bj3350637
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease, Annals of Neurology, vol.114, issue.S1, pp.82-87, 1992. ,
DOI : 10.1212/WNL.38.6.943
Oxidative stress and the pathogenesis of Parkinson's disease, Neurology, vol.47, issue.Issue 6, Supplement 3, pp.161-170, 1996. ,
DOI : 10.1212/WNL.47.6_Suppl_3.161S
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free radical biology & medicine 62, pp.111-120, 2013. ,
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. The Canadian journal of neurological sciences, Le journal canadien des sciences neurologiques, vol.11, pp.160-165, 1984. ,
Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, p.310, 1983. ,
Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment, Brain Research, vol.376, issue.1, pp.117-124, 1986. ,
DOI : 10.1016/0006-8993(86)90905-4
Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease? Cellular and molecular neurobiology 21, pp.215-235, 2001. ,
Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice, Journal of Neuroscience, vol.25, issue.28, pp.6594-6600, 2005. ,
DOI : 10.1523/JNEUROSCI.0970-05.2005
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover, Annals of Neurology, vol.195, issue.5, pp.689-690410260518, 1989. ,
DOI : 10.1002/ana.410260518
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons ??? A possible novel pathogenetic mechanism in Parkinson's disease, Neuroscience Letters, vol.170, issue.1, pp.136-140, 1994. ,
DOI : 10.1016/0304-3940(94)90258-5
Molecular biology of dopamine-induced apoptosis: possible implications for Parkinson's disease. Methods in molecular medicine 62, pp.73-8773, 2001. ,
Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons, Molecular Neurobiology, vol.18, issue.suppl, pp.149-170, 2009. ,
DOI : 10.1111/j.1600-0773.1980.tb02459.x
A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter, Cell, vol.70, issue.4, pp.539-551, 1992. ,
DOI : 10.1016/0092-8674(92)90425-C
Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules, The Journal of experimental biology, vol.196, pp.251-262, 1994. ,
Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size, The Journal of neuroscience: the official journal of the Society for Neuroscience, vol.20, pp.7297-7306, 2000. ,
Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease, Annals of Neurology, vol.68, issue.5, pp.555-560410430503, 1998. ,
DOI : 10.1212/WNL.47.3.718
Vesicular Transport Regulates Monoamine Storage and Release but Is Not Essential for Amphetamine Action, Neuron, vol.19, issue.6, pp.1271-1283, 1997. ,
DOI : 10.1016/S0896-6273(00)80418-3
URL : http://doi.org/10.1016/s0896-6273(00)80418-3
VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity, Proceedings of the National Academy of Sciences, vol.6, issue.17, pp.9938-9943, 1997. ,
DOI : 10.1097/00001756-199511270-00011
URL : http://www.pnas.org/content/94/18/9938.full.pdf
Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine, Neuron, vol.19, issue.6, pp.1285-1296, 1997. ,
DOI : 10.1016/S0896-6273(00)80419-5
Increased Vulnerability to l-DOPA Toxicity in Dopaminergic Neurons From VMAT2 Heterozygote Knockout Mice, Journal of Molecular Neuroscience, vol.27, issue.3, pp.277-27927277, 2005. ,
DOI : 10.1385/JMN:27:3:277
Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals, Toxicological Sciences, vol.153, issue.1, pp.79-88, 2016. ,
DOI : 10.1093/toxsci/kfw106
Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration, Journal of Neuroscience, vol.27, issue.30, pp.8138-81480319, 2007. ,
DOI : 10.1523/JNEUROSCI.0319-07.2007
URL : http://www.jneurosci.org/content/jneuro/27/30/8138.full.pdf
Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women, Human Molecular Genetics, vol.15, issue.2, pp.299-305, 2006. ,
DOI : 10.1093/hmg/ddi445
Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum, Journal of Neuroscience, vol.34, issue.24, pp.8210-8218, 2014. ,
DOI : 10.1523/JNEUROSCI.5456-13.2014
Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour, Journal of Psychiatry & Neuroscience, vol.41, issue.2, pp.169-181, 2016. ,
DOI : 10.1503/jpn.150028
URL : https://hal.archives-ouvertes.fr/hal-01542305
Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons, Nature Neuroscience, vol.4, issue.4, pp.560-5634245, 2016. ,
DOI : 10.1016/j.biopsych.2014.03.013
URL : https://hal.archives-ouvertes.fr/hal-01542253
Severe Serotonin Depletion after Conditional Deletion of the Vesicular Monoamine Transporter 2 Gene in Serotonin Neurons: Neural and Behavioral Consequences, Neuropsychopharmacology, vol.143, issue.12, pp.2538-2550, 2011. ,
DOI : 10.1016/j.jneumeth.2004.09.020
URL : https://hal.archives-ouvertes.fr/hal-00665880
Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic, Cell, vol.83, issue.7, pp.1197-1209, 1995. ,
DOI : 10.1016/0092-8674(95)90145-0
URL : http://doi.org/10.1016/0092-8674(95)90145-0
Circling behavior in rats with 6-hydroxydopamine or electrolytic nigral lesions, European Journal of Pharmacology, vol.37, issue.2, pp.339-356, 1976. ,
DOI : 10.1016/0014-2999(76)90042-X
Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat, Experimental Neurology, vol.152, issue.2, pp.259-2776848, 1998. ,
DOI : 10.1006/exnr.1998.6848
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry, Nature, vol.26, issue.7306, pp.622-626, 2010. ,
DOI : 10.1038/nature09159
Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: Studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal da pathway and quantitative recording of rotational behaviour, Pharmacology & Therapeutics. Part B: General and Systematic Pharmacology, vol.2, issue.1, pp.41-47, 1976. ,
DOI : 10.1016/0306-039X(76)90017-9
6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome, Pharmacology & Therapeutics. Part B: General and Systematic Pharmacology, vol.2, issue.1, pp.37-40, 1976. ,
DOI : 10.1016/0306-039X(76)90016-7
Dopamine neuron systems in the brain: an update, Trends in Neurosciences, vol.30, issue.5, pp.194-202006, 2007. ,
DOI : 10.1016/j.tins.2007.03.006
Dopamine receptor pharmacology, Trends in Pharmacological Sciences, vol.15, issue.7, pp.264-270, 1994. ,
DOI : 10.1016/0165-6147(94)90323-9
Targeted disruption of the tyrosine hydroxylase gene reveals that
catecholamines are required for mouse fetal development, Nature, vol.374, issue.6523, pp.640-643, 1995. ,
DOI : 10.1038/374640a0
Trafficking of Vesicular Neurotransmitter Transporters, Traffic, vol.417, issue.10, pp.1425-1436, 2008. ,
DOI : 10.1091/mbc.11.5.1801
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0854.2008.00771.x/pdf
The transport of neurotransmitters into synaptic vesicles, Current Opinion in Neurobiology, vol.2, issue.5, pp.586-594, 1992. ,
DOI : 10.1016/0959-4388(92)90023-E
The Neurotransmitter Cycle and Quantal Size, Neuron, vol.55, issue.6, pp.835-858, 2007. ,
DOI : 10.1016/j.neuron.2007.09.001
URL : http://doi.org/10.1016/j.neuron.2007.09.001
Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for Parkinsonism, Molecular and Cellular Biology, vol.21, issue.16, pp.5321-53315321, 2001. ,
DOI : 10.1128/MCB.21.16.5321-5331.2001
Mitochondrial dysfunction in Parkinson's disease, Journal of Neurochemistry, vol.89, issue.Suppl 1, pp.216-23113731, 2016. ,
DOI : 10.1016/j.ajhg.2011.06.008
Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria, Journal of Neurochemistry, vol.265, issue.3, pp.1127-1137, 1999. ,
DOI : 10.1038/jcbfm.1987.130
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases, Nature, vol.175, issue.7113, pp.787-795, 2006. ,
DOI : 10.1212/WNL.43.12.2689
Oxidative stress and Parkinson's disease. Frontiers in neuroanatomy 9, 2015. ,
Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease, Experimental Neurology, vol.156, issue.1, pp.138-1487008, 1998. ,
DOI : 10.1006/exnr.1998.7008
Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine, Brain Research, vol.692, issue.1-2, pp.233-243, 1995. ,
DOI : 10.1016/0006-8993(95)00674-F
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration, Parkinsonism & Related Disorders, vol.21, issue.9, pp.1013-1022, 2015. ,
DOI : 10.1016/j.parkreldis.2015.07.009
Regulatory Mechanisms of Dopamine Biosynthesis at the Tyrosine Hydroxylase Step, Annals of the New York Academy of Sciences, vol.16, issue.1 Presynaptic M, pp.1-5, 1984. ,
DOI : 10.1139/v82-386
Elucidation of the Rate-Limiting Step in Norepinephrine Biosynthesis in the Perfused Guinea-Pig Heart, The Journal of pharmacology and experimental therapeutics, vol.148, pp.1-8, 1965. ,
Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release, Synapse, vol.96, issue.1, pp.15-22, 2002. ,
DOI : 10.1016/S0306-4522(99)00539-4
Autoreceptor Regulation of Dopamine Synthesis, Annals of the New York Academy of Sciences, vol.35, issue.1 Presynaptic R, pp.323-343, 1990. ,
DOI : 10.1021/bi00458a003
Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein, European Journal of Pharmacology, vol.504, issue.1-2, pp.27-32049, 2004. ,
DOI : 10.1016/j.ejphar.2004.09.049
Immunochemical analysis of dopamine transporter protein in Parkinson's disease, Annals of Neurology, vol.643, issue.4, pp.530-539410410417, 1997. ,
DOI : 10.1212/WNL.42.5.1071
Etiology and pathogenesis of Parkinson's disease. Annual review of neuroscience 22, pp.123-144, 1999. ,
Behavioral and neurochemical effects induced by reserpine in mice, Psychopharmacology, vol.13, issue.Suppl2, pp.457-467, 2016. ,
DOI : 10.2165/00002512-199813050-00002
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter, Nature, vol.379, issue.6566, pp.606-612379606, 1996. ,
DOI : 10.1038/379606a0
Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter, European Journal of Neuroscience, vol.303, issue.10, pp.3499-3511, 1999. ,
DOI : 10.1016/0306-4522(81)90003-8
Infantile parkinsonism-dystonia and elevated dopamine metabolites in CSF, Neurology, vol.62, issue.10, pp.1872-1874, 2004. ,
DOI : 10.1212/01.WNL.0000126440.16612.51
Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia, Journal of Clinical Investigation, vol.119, pp.1595-1603, 2009. ,
DOI : 10.1172/JCI39060
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study, The Lancet Neurology, vol.10, issue.1, pp.54-62, 2011. ,
DOI : 10.1016/S1474-4422(10)70269-6
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons, Proceedings of the National Academy of Sciences, vol.97, issue.12, pp.11035-110401831768100, 2003. ,
DOI : 10.1073/pnas.120166397
Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background, European Journal of Neuroscience, vol.11, issue.1, pp.120-126, 2004. ,
DOI : 10.1016/S0166-2236(02)02192-6
Parkinson's disease: animal models and dopaminergic cell vulnerability, Frontiers in neuroanatomy, vol.8, issue.155, p.155, 2014. ,
DOI : 10.3389/fnana.2014.00155
URL : http://journal.frontiersin.org/article/10.3389/fnana.2014.00155/pdf